Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
暂无分享,去创建一个
R. Giugliano | E. Braunwald | C. Cannon | S. Murphy | E. Bohula | M. Blazing | A. Tershakovec | Jennifer A. White | Jing Zhou
[1] R. Giugliano,et al. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.
[2] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[3] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[4] E. Braunwald. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. , 2012, European heart journal.
[5] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[6] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.